Published on 2026-01-26T18:30:14.000Z, a significant recall alert has been issued by Mercury Pharmaceuticals Ltd. The company is recalling the remaining stock of paliperidone pre-filled syringes as a precautionary measure. This decision comes after Good Manufacturing Practice (GMP) deficiencies were cited during a recent inspection at the finished product manufacturing site.
For quick navigation: What changed? | Who is affected? | FAQ | Conclusion | Disclaimer | Full Announcement
What changed?
The recall is a result of GMP deficiencies identified during an inspection. These deficiencies may impact the quality of the paliperidone pre-filled syringes, which are used for the treatment of certain psychiatric conditions. The inspection highlighted issues that could potentially affect the safety and efficacy of the product.
Impact on Patients and Healthcare Providers
Patient safety is the top priority. Healthcare providers and patients should be aware of this recall to ensure that any potential risks associated with the use of these pre-filled syringes are mitigated. The recall affects all remaining stock of paliperidone pre-filled syringes manufactured by Mercury Pharmaceuticals Ltd.
Who is affected?
This recall affects patients who are currently using or are scheduled to use the paliperidone pre-filled syringes, as well as healthcare providers who prescribe or administer this medication. It is crucial for these groups to be informed about the recall to take appropriate action.
Actions for Healthcare Providers
Healthcare providers should immediately stop using the recalled products and return them to the manufacturer. They should also inform their patients about the recall and discuss alternative treatment options. Patients who have been using the recalled paliperidone pre-filled syringes should contact their healthcare provider for advice on next steps.
FAQ
- What is the reason for the recall? The recall is due to GMP deficiencies found during an inspection.
- What products are affected? The recall affects all remaining stock of paliperidone pre-filled syringes manufactured by Mercury Pharmaceuticals Ltd.
- What should patients do? Patients should contact their healthcare provider for advice on alternative treatments.
Conclusion
In conclusion, the recall of paliperidone pre-filled syringes by Mercury Pharmaceuticals Ltd is a precautionary measure to ensure patient safety. It is essential for all stakeholders, including patients and healthcare providers, to be aware of this recall and take necessary actions.
Disclaimer
This information is provided for informational purposes only and is not intended to be legal advice. Healthcare professionals should consult the official recall notice and relevant guidelines for detailed information and instructions.
For full information about the announcement, see the link below.
https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-mercury-pharmaceuticals-ltd-paliperidone-mercury-pharma-prolonged-release-suspension-for-injection-in-pre-filled-syringes-el-26-a-slash-01